# A Ph2 Study to Evaluate the Safety, Efficacy and Tolerability of HT-6184 and Semaglutide in Obese Participants With T2DM

> **NCT07172867** · PHASE2 · WITHDRAWN · sponsor: **Halia Therapeutics, Inc.**

## Conditions studied

- Diabetes Mellitus, Type 2
- Obesity

## Interventions

- **DRUG:** HT-6184
- **DRUG:** HT-6184 Matching Placebo
- **DRUG:** Semaglutide 1 mg

## Key facts

- **NCT ID:** NCT07172867
- **Lead sponsor:** Halia Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2026-01-06
- **Primary completion:** 2026-01-23
- **Final completion:** 2026-01-23
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Business decision to move away from this indication with this intervention, and low enrollment.
- **Last updated:** 2026-02-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07172867

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07172867, "A Ph2 Study to Evaluate the Safety, Efficacy and Tolerability of HT-6184 and Semaglutide in Obese Participants With T2DM". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT07172867. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*